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| INTRODUC TI ON
The past decades have witnessed extensive progress in unraveling cellular and molecular mechanisms of immune regulation in asthma, allergic diseases, organ transplantation, autoimmune diseases, tumor biology, and chronic infections. been developed to date. [3] [4] [5] [6] [7] [8] In addition, a number of promising small molecule drugs and vaccines are in the development pipeline. [9] [10] [11] This new era is now calling for the development of biomarkers and phenoand endotyping of diseases for customized patient care, which is termed stratified medicine, precision medicine, or personalized medicine. 4 Distinguishing phenotypes of a complex disease covers the observable clinically relevant properties of the disease but does not show a direct relationship to disease etiology and pathophysiology. In a complex condition, such as asthma, different pathogenetic mechanisms can induce similar clinical manifestations; however, they may require different treatment approaches. 12, 13 These pathophysiological mechanisms underlying disease subgroups are addressed by the term "endotype." [12] [13] [14] Classification of complex diseases based on the concept of endotypes provides advantages for epidemiological, genetic, and drug-related studies. Accurate endotyping by using reliable biomarkers reflects the natural history of the disease and aims to predict the response to (targeted) treatments. 15 Recent studies have focused on better understanding of endotypes and phenotypes of allergic diseases, asthma, allergic and chronic rhinosinusitis ± nasal polyps, chronic obstructive pulmonary disease, and on the development of biomarkers including novel interleukins and microRNAs that regulate their expression to stratify patients.
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| BA S IC MECHANIS MS OF ALLERG IC DIS E A S E S-KE Y QUE S TIONS
| Structural and functional biology of allergenswhere are we at?
Cloning of allergen cDNAs and sequencing of purified natural aller- by Dall'Antonia et al 19 Structural data of allergens allow the study of of allergic diseases, asthma, allergic and nonallergic rhinitis, and new approaches to the diagnosis and treatment of drug hypersensitivity reactions are discussed in further detail. In the third section, unmet needs and future research areas for the treatment of allergic diseases are highlighted with topics on food allergy, biologics, small molecules, and novel therapeutic concepts in allergen-specific immunotherapy for airway disease. Unknowns and future research needs are discussed at the end of each subsection.
K E Y W O R D S
allergy, exposome, microbiome, neuroimmune, respiratory viral infections
How to expand the understanding of allergens and allergic sensitization?
• Provide structures of homologous allergens to study cross-reactivity • Define "susceptibility to allergic sensitization" at the molecular and mechanistic level cross-reactivities between related allergens, 20 or the design of allergens with altered IgE epitopes as vaccine candidates for AIT. 21 The location of IgE-binding epitopes can be determined based on allergen structures and experimental data. 22 
| T-regulatory and B-regulatory cells
Immune regulation is an important function of the immune system to tolerate self-tissues and non-self-environmental allergens. 54 Extensive research is ongoing in this area.
To date, there are no biologicals that induce T-and B-regulatory responses in patients; however, various modes of AIT represent major stimulators of these cells in an allergen-specific manner in vivo.
| Neuroimmune mechanisms in allergic inflammation
It is becoming increasingly clear that immune cells do not act alone and that cross talk and reciprocal regulation between neural and immune systems are essential in the pathophysiology of allergic diseases including allergic asthma, atopic dermatitis, and food allergies. 55, 56 Immune and neuronal cell types are found in large numbers at skin and mucosal barrier surfaces and are in close contact with each other forming a neuronal-immune cell network. In addition to mediating allergic responses via immune responses, these proinflammatory mediators also directly activate sensory neurons that regulate itch, cough, sneezing, bronchoconstriction, and alterations in gastrointestinal motility. 59 On stimulation, sensory and autonomic neurons release neuropeptides and neurotransmitters such as substance P, neurokinin A, neuromedin U (NMU), calcitonin gene-related peptide, vasoactive intestinal peptide, acetylcholine, and norepinephrine that signal immune cells. 55 In the airways, calcitonin gene-related peptide is released by sensory nerves, which has been shown to inhibit dendritic cell maturation and allergen-specific T-cell responses. 61 In the gut, ILC2 cells were shown to express Nmur1, a receptor for the neuropeptide NMU. ILC2s live in close proximity to NMU-producing nerve
The exposome: The exposome includes the entire environmental exposures of an individual from conception throughout the whole life. Early-life events such as mode of delivery, breastfeeding, mother's diet, lifestyle and health status, antibiotics, and other drug usage in pregnancy and early childhood, early-life environment (ie, siblings, pets at home, proximity to farm animals and green areas, usage of primary farm products) can significantly influence the epigenetic regulation of immune system and tissue cells 
| Exposome, environmental factors and allergy
The rising trend in allergies is associated with changes in lifestyle and the control of infections which, taken together, seem to result in an "under-challenged" immune system. 65, 66 On the other hand, lifestyle changes and indoor and outdoor environmental pollut- with the human body but also environment-environment interactions will enable us to develop prevention strategies for allergies.
| Role of the microbiome and diet in immune responses
Enormous varieties of microbes colonize the skin and mucosal body surfaces. These microbes are organized within complex community structures, whose composition is dependent on the specific body site examined. It is increasingly appreciated that the microbiome interacts intimately with mucosal immune processes and disrupted communication between the microbiome and the host due to altered microbiome composition and/or metabolism is thought to negatively influence immune homeostatic networks and may play a role in immune hypersensitivity to environmental exposures, such as allergens. 75 A number of studies have consistently demonstrated that an altered gut, lung, nasal, or skin microbiome is associated with, and sometimes precedes, allergic sensitization and inflammation. 76, 77 In particular, early-life events such as mode of delivery, breastfeeding, mother's diet and health status, antibiotics, and other drug usage in pregnancy and early childhood, early-life environment (ie, siblings, pets at home, proximity to farm animals and green areas, usage of primary farm products) can significantly influence the timing of bacterial colonization and establishment. [78] [79] [80] However, one of the most potent modulators of microbiota composition is diet, as consumed foods provide the fuel for microbial metabolic activities. 81 For example, microbiota-accessible carbohydrates (MAC) are complex carbohydrates found in dietary fibers that contribute to microbial diversity and generation of metabolites, such as short-chain fatty acids (SCFAs). 82 SCFAs promote regulatory immune responses, and high SCFA levels early in life are associated with protection from atopic sensitization. 83 In contrast, a high-fat diet is associated with negative effects on microbiota composition and metabolism.
Despite increasing awareness of the importance of microbiome-diet interactions in health and disease, the molecular basis for these multidirectional functional interactions is only beginning to be Hot spots in environmental health research CD69+ upregulation. 102 Therefore, an understanding of the predominant type and underlying mechanisms of mucosal inflammation triggered by common viral infections will allow identification of targets for better management of chronic airway inflammatory diseases. in AIT. 108 Another example is an EAACI Position Paper, which overviews current concepts in tolerance-inducing mechanisms aimed to highlight potential biomarkers which may be of predictive value for determining responders to AIT in clinical trials. 15 However, there is an urgent need for further harmonization and clinical validation of methodological determinants in AIT clinical study design, which can only be achieved by international collaboration of clinical experts, methodologists, and regulatory authorities. (Figure 3) . 13, 112 The "omics" revolution is based on platform technologies in genomics (by far the most robust), metabolomics, proteomics, epigenomics, transcriptomics, lipidomics, and microbiomics to generate vast global datasets, and advanced bioinformatics to interrogate and interpret the datasets using machine learning and artificial intelligence (Figure 4) . 113 Such analysis of population-based datasets can reveal novel insights to underpin therapeutic selection from an expanded range of precise biologicals. 114 Examples are emerging from patients with inborn errors of immunity (IEI) in whom the genetically defined defect can be specifically targeted with therapeutics. 115, 116 The functional utility of data from the omics platforms will be further enhanced by the public release of omics datasets including Genotype-Tissue Expression (GTEx) 117 and Encyclopaedia of DNA Elements (ENCODE). 
| Respiratory viral infections and allergy
| D IAG NOS TI C CHALLENG E S AND REG UL ATORY CONS IDER ATIONS
| Clinical trials for the treatment of allergic diseases
| Allergic rhinitis and nonallergic rhinitis
Chronic rhinitis (CR) is one of the most common diseases globally, with a considerable financial burden. 126, 127 At present, CR is
Unmet needs in precision medicine
• Consensus on endotypes and clinically applicable biomarkers for distinct allergic disorders (TCT) and demonstrated that this technique has higher sensitivity, specificity, and positive predictive value for inflammation in the inferior turbinates than for inflammation in the maxillary sinus. 135 Thus, the TCT might also be used in the studies on CR, especially NARES.
In conclusion, there is increasing evidence that local IgE and nasal cytology are useful clinical diagnostic markers in CR and might represent the way forward especially for studies differentiating the endotypes of AR and NAR in the future.
| New approaches to the diagnosis and treatment of drug hypersensitivity reactions
Drug hypersensitivity reactions (DHRs) are defined as adverse effects of pharmaceutical formulations that clinically resemble allergy. Drug allergies are defined as DHRs for which a definite immunological mechanism, IgE-or T cell-mediated, is demonstrated. 136 DHRs constitute an important health problem, affecting more than 7% of the population, 137 for whom drugs, such as beta-lactam antibiotics and nonsteroidal anti-inflammatory drugs, are essential for treatment of common diseases. 138, 139 Based on the clinical characteristics of DHRs, different phenotypes have been identified, 137 although the lack in understanding the underlying mechanisms of many DHRs has hampered the definition of endotypes and identification of biomarkers.
140,141
The classification of DHRs based on the time elapsed between drug administration and development of symptoms is still a matter of debate, because it is difficult to establish a cutoff point to distinguish between immediate and nonimmediate DHRs. 13, 136, 141 These data are relevant for defining phenotypes and establishing an accurate diagnosis and specific treatment. An important recent advance has been the inclusion of "Drug hypersensitivity" as a subsection in the International Classification of Diseases (ICD)-11.
140
The diagnosis of DHR is mainly based on skin tests and drug provocation tests, methods that are not free of risk, still lack standardization, and differ depending on the drug, mechanisms, and even the health system. [142] [143] [144] There is an urgent need for developing new in vitro diagnostic tests or improving those already existing, 138 such as basophil activation test, 145, 146 to improve the diagnostic workup.
The complexity of DHR diagnosis and its lack of optimal specificity lead to an over-diagnosis. This is an important problem, as patients "labeled" as allergic receive alternative treatments that are usually less effective and more toxic, so "de-labeling" constitutes a public health measure. 147 Primary care physicians are often the first point of contact for patients with DHRs; thus, they have a key role in diagnosis and need specific training. 148 Although the specific treatment of DHRs is avoiding the drug involved and those chemically related, desensitization is nowadays a frequent option. [149] [150] [151] In that sense, rapid drug desensitization is a cost-effective technique that activates inhibitory mechanisms and permits patients to receive the first-choice medications to which they are allergic.
149,150
Research needs for DHRs • Could nasal cytology be used in the study of chronic rhinitis, especially for the differential diagnosis of chronic rhinitis?
• Can we provide the diagnostic standard of local IgE determination for allergic rhinitis and local allergic rhinitis?
• Can we provide the diagnostic standard of nasal eosinophil count for nonallergic rhinitis with eosinophilia syndrome?
| UNME T NEEDS AND FUTURE RE S E ARCH ARE A S IN TRE ATMENT OF ALLERG I C D IS E A S E S
| How to treat food allergy in the future: new developments and concepts
We are observing a pandemic increase in food allergy and approaching an era of efficient treatments. In peanut allergy oral immunotherapy (OIT), phase III studies on AR101 152 in peanut allergic patients and phase II(b) and III studies on epicutaneous immunotherapy (EPIT) for milk and peanut 153, 154 have been conducted. The FDA application for AR101 is submitted, while peanut EPIT submission has been retracted to provide additional technical information.
Different ways of application differ with regard to efficacy of desensitization; however, all current applications are linked to an avoidance regimen and it is unclear how long the individual treatment needs to be applied. Consistent data from conventional high-dose milk, peanut, and egg OIT report good efficacy with regard to desensitization. 155, 156 Therefore, in addition to these highly standardized products, OIT using conventional food sources may become a more frequent treatment offered by clinicians in the community as a result of excessive demand in the absence of guidelines and recommendations. As a first step, the European Academy of Allergy and Clinical
Immunology (EAACI) stated to consider OIT for these three foods in settings with the appropriate infrastructure and experience. 155 The major issues in treating food allergy by immunotherapy are safety, the low rate of tolerance induction, 155 a high rate of side effects and dropouts, 153 a lack of understanding of the optimal dose and time of treatment, and the existence of only few, suboptimal biomarkers that predict treatment response and how to perform multifood OIT. 13, 157, 158 These limitations are addressed in numer- 76, 166 ; (e) the application of biologics either alone 167, 168 or as adjuvants of OIT 169, 170 and EMA approved mepolizumab, reslizumab, and benralizumab for adult uncontrolled asthma and dupilumab for atopic dermatitis in adolescents and adults, and these biologics are integrated in current guidelines and position papers. 12, 175, 185, 186 New indications for these biologicals can be expected in the near future. 184, 187 Novel data arising from a long pipeline of cytokine and chemokine receptor targeting drugs will lead to additional treatment options and change the landscape of therapeutics in other atopic diseases including food allergy, chronic rhinosinusitis with nasal polyps, 12, 188 and systemic mastocytosis. 189 Biologics may also increase efficacy and safety of AIT.
Phase II trials of biologics targeting type-2 pathways beyond IL-4, IL-5, and IL-13 are encouraging. Tezepelumab blocking the TSLP receptor showed efficacy in uncontrolled asthma independent of eosinophil counts. 190 Nemolizumab blocks the IL-31R-alpha and reduces pruritus and to a certain extent also dermatitis severity. 191 It
Unknowns in the treatment of food allergy
• Which markers predict treatment response?
• Which markers can be used to monitor tolerance development?
• What is the optimal dose and time of treatment?
• Is there a role for biologics to improve safety and efficacy of immunotherapeutic approaches?
• What is the best route to apply immunotherapy?
• How can we implement oral immunotherapy safely in a community setting?
• How to modify allergen formulations for tolerance induction?
Gaps in the treatment of allergic disease with biologics
• How to predict treatment response?
• Will new biologics help to promote tolerance induction?
• How to define precision medicine approaches to treat severe and complex atopic phenotypes?
• Long-term side effects of biologics?
• Safety and efficacy of biologics in childhood, in pregnancy, and in elderly?
• Novel biomarkers and sets of biomarkers will be needed.
• Treatment algorithms and guidelines for biologics usage are needed.
is a good example for biologicals with the potential to be combined with a second to achieve better disease control. Another important group of emerging biologics will address mucosal inflammation 44, 192 and upstream events which are key for innate lymphoid cells such as anti-IL-25 and anti-IL-33.
Costs are an important factor when prescribing biologics.
Currently, direct treatment expenses only partially contribute to the overall disease-associated financial burden. 193, 194 Thus, costs related to comorbidities 195 and the impact of biologics on these factors will be key. The development of biomarkers, prediction models, 5, 196 the design of trials comparing different biologics and the implementation of strategies to investigate the safety, function, and efficacy in children, the elderly, and pregnant women represent additional crucial challenges that need to be answered in the near future.
| Small molecules for the treatment of allergic asthma
Several targeted therapeutic options for asthma and related con- 
| Novel therapeutic concepts in AIT for airway disease
Allergen-specific immunotherapy not only reduces symptoms in patients with AR, 106 Despite this positive profile, AIT is only used for highly selected patient groups in most countries in Europe. 109 The reasons for this limited penetration are multifold 16, 103, 222 but the long duration of the treatment, the potential side effects especially in groups that could most benefit from AIT, and the inability to predict development of allergic disease and response to AIT treatment are among the most important ones. Recently, EAACI has been very active in providing guidelines for immunotherapy 109, 223 to help physicians and patients in their decisions. However, for further expansion of AIT, we must influence the balance between allergenicity and immunogenicity, which can improve both duration of treatment and create a better side effect profile. Furthermore, we need greater understanding of the molecular mechanisms underlying the development
Research needs for treatment with novel small molecules
• Sensitive and reliable point-of-care biomarkers to identify potential responders and to monitor (long-term) effects of anti-lipid mediator small molecules (LM, LTRA, CRTH2
antagonists).
• Combining LTRA and CRTH2 antagonists may be beneficial in patients with type 2 inflammatory conditions and, hence, warrants further clinical investigation.
• Since both DP2/CRTH2 receptors and CysLT1 receptors are present on both immune/inflammatory and structural cells, apart from anti-inflammatory activity, blocking these receptors may potentially have disease-modifying effects ("anti-remodeling").
of respiratory allergic disease and of AIT at the level of the individual patient, facilitating better patient stratification for AIT to further improve optimal personalized treatment.
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| CON CLUS IONS
Our specialty has been evolving at full speed with the introduc- 
